Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 32Carcinoma, Hepatocellular 23Carcinoma, Non-Small-Cell Lung 16Small Cell Lung Carcinoma 11Ovarian Neoplasms 11Colorectal Neoplasms 11Sarcoma 9Lung Neoplasms 9Nasopharyngeal Carcinoma 7Neoplasms 6Breast Neoplasms 6Triple Negative Breast Neoplasms 5Head and Neck Neoplasms 5Glioma 5Esophageal Neoplasms 5Cholangiocarcinoma 5Recurrence 4Pancreatic Neoplasms 4Osteosarcoma 4Esophageal Squamous Cell Carcinoma 4Biliary Tract Neoplasms 4Advanced Gastric Cancer 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Solid Tumor 3Neoplasm Metastasis 3NSCLC 3Melanoma 3Gastrointestinal Neoplasms 3

Interventions

camrelizumab 2spartalizumab 1apatinib 1S 1 (combination) 1Neoadjuvant Therapy 1Hyperthermic Intraperitoneal Chemotherapy 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Gastric Adenocarcinoma × apatinib × Clear all
NCT04174339 2019-11-22

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Fujian Cancer Hospital

Phase NA Unknown
20 enrolled
Gastrointestinal

Advanced Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡